Page last updated: 2024-08-24

aripiprazole and Diabetes Mellitus

aripiprazole has been researched along with Diabetes Mellitus in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (72.73)	29.6817
2010's	3 (27.27)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Grossman, F; Hassan, M; Meyer, K; O'Day, K; Rajagopalan, K	1
Baker, RA; Citrome, L; Hebden, T; Kalsekar, I	1
Connolly, JG; Schneeweiss, MC; Toomey, TJ	1
Barnett, AH; Knapp, M; L'Italien, GJ; Loze, JY; Millar, HL; van Baardewijk, M	1
Bogers, JP; Starrenburg, FC	1
DeLorenze, G; L'Italien, G; McQuade, R; Newcomer, J; Oliveria, SA; Quesenberry, CP; Tsai, AL; Willey, VJ; Yood, MU	1
Cohen, D; Correll, CU	1
Dubois, D	1
De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M	1
Wooten, J	1
Blonde, L; Gutterman, EM; Hanssens, L; Kan, HJ; Kim, MS; L'Italien, GJ; McQuade, RD	1

Reviews

4 review(s) available for aripiprazole and Diabetes Mellitus

Article	Year
A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Current medical research and opinion, 2014, Volume: 30, Issue:8 Topics: Adult; Antipsychotic Agents; Aripiprazole; Carbohydrate Metabolism; Diabetes Mellitus; Glucose Metabolism Disorders; Humans; Hyperlipidemias; Insulin Resistance; Lipid Metabolism; Overweight; Piperazines; Quinolones; Weight Gain	2014
How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. European psychiatry : the journal of the Association of European Psychiatrists, 2009, Volume: 24, Issue:3 Topics: Adiponectin; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus; Humans; Leptin; Obesity; Olanzapine; Piperazines; Quinolones; Receptor, Muscarinic M3; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Histamine; Serotonin 5-HT1 Receptor Agonists; Thiazoles; Weight Gain	2009
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Current opinion in pediatrics, 2005, Volume: 17, Issue:2 Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Cardiomyopathies; Child; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Drug Interactions; Drug Overdose; Dry Eye Syndromes; Humans; Hyperlipidemias; Hypotension; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Seizures; Thiazoles	2005
Metabolic effects of the atypical antipsychotics. Southern medical journal, 2007, Volume: 100, Issue:8 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles	2007

Trials

2 trial(s) available for aripiprazole and Diabetes Mellitus

Article	Year
UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). European archives of psychiatry and clinical neuroscience, 2009, Volume: 259, Issue:4 Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Coronary Disease; Cost of Illness; Costs and Cost Analysis; Diabetes Mellitus; Female; Follow-Up Studies; Health Resources; Health Services; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia; United Kingdom; Young Adult	2009
Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:5 Topics: Adult; Algorithms; Aripiprazole; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Humans; Hypertension; Incidence; Male; Piperazines; Prevalence; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia	2008

Article

Year

UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study).

European archives of psychiatry and clinical neuroscience, 2009, Volume: 259, Issue:4

Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Coronary Disease; Cost of Illness; Costs and Cost Analysis; Diabetes Mellitus; Female; Follow-Up Studies; Health Resources; Health Services; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia; United Kingdom; Young Adult

2009

Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care.

The Journal of clinical psychiatry, 2008, Volume: 69, Issue:5

Topics: Adult; Algorithms; Aripiprazole; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Humans; Hypertension; Incidence; Male; Piperazines; Prevalence; Prospective Studies; Quinolones; Risk Assessment; Risk Factors; Schizophrenia

2008

Other Studies

5 other study(ies) available for aripiprazole and Diabetes Mellitus

Article	Year
Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data. Journal of medical economics, 2013, Volume: 16, Issue:7 Topics: Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus; Hospitalization; Humans; Isoindoles; Lurasidone Hydrochloride; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Piperazines; Quinolones; Recurrence; Schizophrenia; Thiazoles; United States	2013
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011. Psychiatric services (Washington, D.C.), 2015, Volume: 66, Issue:6 Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Benzodiazepines; Blood Glucose; Child; Child, Preschool; Cohort Studies; Conduct Disorder; Databases, Factual; Depressive Disorder; Diabetes Mellitus; Female; Glycated Hemoglobin; Guideline Adherence; Humans; Hyperkinesis; Male; Mass Screening; Mental Disorders; Olanzapine; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Risperidone; Thiazoles	2015
The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study. Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:9 Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Cohort Studies; Diabetes Mellitus; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Piperazines; Quinolones; Retrospective Studies; Thiazoles; United States	2009
Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Diabetic Ketoacidosis; Dibenzothiazepines; Humans; Mass Screening; Olanzapine; Piperazines; Predictive Value of Tests; Prospective Studies; Quetiapine Fumarate; Quinolones; Severity of Illness Index	2009
Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. Diabetes care, 2006, Volume: 29, Issue:10 Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes Mellitus; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia	2006